Eton Pharmaceuticals appoints David Krempa as Chief Business Officer

Eton Pharmaceuticals, Inc.

Effective March 1, 2023, David Krempa promoted from SVP Business Development & IR to Chief Business Officer.
Annual salary of $385,000; eligible for discretionary annual bonus and participates in 2018 Equity Incentive Plan.
Severance: 6 months base salary if terminated without cause or for good reason; accelerated vesting on change-in-control within 12 months.
Krempa has been with Eton since 2017, previously serving as SVP, VP, and Executive Director of Business Development.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Krempa

Chief Business Officer

ETON · Eton Pharmaceuticals, Inc.

Effective: 2023-03-01
Filed: March 1, 2023, 6:59 PM ET

Effective March 1, 2023, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) has appointed David Krempa to the position of Chief Business Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Krempa was appointed as Chief Business Officer at Eton Pharmaceuticals, Inc..

Action: appointed
Role: Chief Business Officer

Exact text from the filing

Effective March 1, 2023, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) has appointed David Krempa to the position of Chief Business Officer.

View on SEC.gov

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006339

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.